The invention provides compositions and methods for reducing oxygen concentration in the environment of or promoting the expression or function of at least one hypoxia inducible factor (HIF) in one or more dysfunctional meibomian glands (MGs), utilizing a low oxygen mimetic agent capable of promoting the expression or function of at least one HIF and mimicking a low oxygen environment, or a combination thereof, to improve MG functions.

The invention provides compositions and methods for reducing oxygen concentration in the environment of or promoting the expression or function of at least one hypoxia inducible factor (HIF) in one or more dysfunctional meibomian glands (MGs), utilizing a low oxygen mimetic agent capable of promoting the expression or function of at least one HIF and mimicking a low oxygen environment, or a combination thereof, to improve MG functions.

Provided is a method of treating cancer cells localized in the lung by administering to such patients a therapeutically effective amount of a liposomal annamycin formulation (L-Ann).

Provided is a method of treating cancer cells localized in the lung by administering to such patients a therapeutically effective amount of a liposomal annamycin formulation (L-Ann).

Described is a method for treating or preventing an infection, such as an infection associated with Staphylococcus epidermidis such as a Health-Care Associated infection, a wound, a sore, an ulcer, a burn. The method includes applying a treatment preparation to a treatment site, the treatment preparation has a first component having a single amino acid, said single amino acid being leucine, and a second component having an active chlorine compound.

Described is a method for treating or preventing an infection, such as an infection associated with Staphylococcus epidermidis such as a Health-Care Associated infection, a wound, a sore, an ulcer, a burn. The method includes applying a treatment preparation to a treatment site, the treatment preparation has a first component having a single amino acid, said single amino acid being leucine, and a second component having an active chlorine compound.

A method of forming metal nanoparticles includes applying a substance to an area of interest, applying cold plasma to the area of interest, and synthesizing nanoparticles from the substance using the cold plasma in the area of interest, wherein the substance is a solution that contains metal ions, and the nanoparticles synthesized are metallic in nature.

A method of forming metal nanoparticles includes applying a substance to an area of interest, applying cold plasma to the area of interest, and synthesizing nanoparticles from the substance using the cold plasma in the area of interest, wherein the substance is a solution that contains metal ions, and the nanoparticles synthesized are metallic in nature.

Disclosed are a sensitizing composition for thermal cancer therapy using electromagnetic waves and a method of treating cancer using the composition. The sensitizing composition includes a metal ion, a metal ion-bound material, metal ion-noncovalently bound apotransferrin (transferrin), or a metal ion-noncovalently bound apotransferrin derivative. The sensitizing composition enables selective delivery of the metal ion to tumorous tissue when administered in vivo, and thus the generation of heat in tumorous tissue in which the metal ion accumulates is increased upon thermal cancer therapy using electromagnetic waves, thereby maximizing efficacy of thermal cancer therapy using electromagnetic waves in treating cancer. Thermal therapy using the sensitizing composition effectively treats cancer without pain or side effects and is thus expected to be widely useful in anticancer treatment as monotherapy, and/or in combination with chemotherapy, radiation therapy, or a combination thereof, ultimately increases the potential to cure cancer.

Disclosed are a sensitizing composition for thermal cancer therapy using electromagnetic waves and a method of treating cancer using the composition. The sensitizing composition includes a metal ion, a metal ion-bound material, metal ion-noncovalently bound apotransferrin (transferrin), or a metal ion-noncovalently bound apotransferrin derivative. The sensitizing composition enables selective delivery of the metal ion to tumorous tissue when administered in vivo, and thus the generation of heat in tumorous tissue in which the metal ion accumulates is increased upon thermal cancer therapy using electromagnetic waves, thereby maximizing efficacy of thermal cancer therapy using electromagnetic waves in treating cancer. Thermal therapy using the sensitizing composition effectively treats cancer without pain or side effects and is thus expected to be widely useful in anticancer treatment as monotherapy, and/or in combination with chemotherapy, radiation therapy, or a combination thereof, ultimately increases the potential to cure cancer.